Navigation Links
New Drug May Help Patients With Irregular Heartbeat Avoid Stroke
Date:2/11/2011

By Kathleen Doheny
HealthDay Reporter

THURSDAY, Feb. 10 (HealthDay News) -- A new anti-clotting drug works better than aspirin for stroke prevention in some patients with the common, sometimes lethal, heart rhythm problem known as atrial fibrillation, according to research presented Thursday.

The new drug, apixaban, is not yet approved for use by the U.S. Food and Drug Administration. But study co-author Dr. Hans-Christoph Diener said the pill "reduced stroke risk [in patients with atrial fibrillation] by 55 percent, compared to aspirin." He believes that "the results of this clinical trial will change clinical practice."

Diener, of the department of neurology and the Stroke Center at University Hospital Essen in Germany, presented the findings at the annual meeting of the American Stroke Association's International Stroke Conference in Los Angeles. The findings are also published online Feb. 10 in the New England Journal of Medicine.

In atrial fibrillation, an irregular beating of the heart causes blood to pool in the heart's chambers. The heart can then "throw" clots up into the arteries supplying blood to the brain, greatly raising the risks for stroke.

Patients with atrial fibrillation are typically prescribed anticoagulants such as warfarin, which is notoriously hard to manage, Diener said at a news conference announcing the study results.

Anticoagulants taken orally can decrease stroke risk by up to 70 percent, according to Diener, but many patients don't comply with the regimen. "About half of all patients refuse to take [warfarin]," he noted, because its use is accompanied by dietary restrictions and the need for frequent blood tests to check blood levels of the drug. Some patients also fear the possibility of a known hazard of warfarin, an excess risk for bleeding.

Many patients who can't or won't take warfarin do take daily aspirin, which cuts the odds of stroke in atrial fibrillation by about 20 percent, according to background information in the study.

In the new study of apixaban, researchers assigned almost 5,600 patients with atrial fibrillation and an increased risk of stroke (due to age or prior stroke, for instance) to one of two groups: apixaban, at 5 milligrams taken twice daily; or aspirin, with doses ranging from 81 to 324 milligrams per day.

The study was done at 522 centers in 36 countries from late 2007 to late 2009. The researchers wanted to compare which drug was better at preventing stroke or blockages due to blood clots elsewhere in the body, called systemic embolism.

Among patients on apixaban, there were 51 strokes or embolisms, or 1.6 percent per year, compared to 113 such events, or 3.7 percent, among those on aspirin.

While apixaban patients experienced 44 major bleeding events, aspirin takers had 39, but the difference was not great enough to be significant from a statistical point of view, Diener said.

The study was funded by Bristol-Myers Squibb and Pfizer, who are working jointly to develop apixaban.

The drug has been shown in previous research to be better at preventing dangerous leg blood clots and lung clots after hip replacement surgery than an older drug, enoxaparin.

Apixaban works by blocking a crucial step in the formation of blood clots. The study of the drug's effects on stroke prevention was actually halted early after one year, Diener said, because of the huge difference found between the two drugs and the superiority of apixaban.

The new drug isn't yet approved by the FDA and Diener couldn't predict when that might happen. Results of another study, a head-to-head comparison of apixaban against warfarin, is due out in August, he said.

A 55 percent reduction in stroke risk compared to aspirin is impressive, said Dr. Larry Chinitz, professor of medicine at the New York University School of Medicine and director of the Heart Rhythm Center at NYU Langone Medical Center. He reviewed the study findings but was not involved in the research.

"I think it's a game-changer" for higher risk patients with atrial fibrillation, he said, such as those over age 70.

The new drug, if approved, ''will certainly improve the lifestyle of patients," Chinitz said, as it won't require, as warfarin does, frequent blood tests or dietary restriction.

Another new anti-clotting drug, Pradaxa (dabigatran), was approved by the FDA in October 2010 for stroke prevention in those with atrial fibrillation. It inhibits an enzyme involved in blood clotting.

More information

To learn stroke's warning signs, head to the American Stroke Association.

SOURCES: Hans-Christoph Diener, M.D., professor and chairman, department of neurology and Stroke Center, University Hospital Essen, Essen, Germany; Larry Chinitz, M.D., director, Heart Rhythm Center, NYU Langone Medical Center, and professor, medicine, NYU School of Medicine, New York City; Feb. 10, 2011, New England Journal of Medicine, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Few Stroke Patients Given Clot-Buster Quickly Enough: Study
2. Non-dopaminergic drug preladenant reduces motor fluctuations in patients with Parkinsons disease
3. Everolimus improves progression-free survival for patients with rare pancreatic cancer
4. Researchers: Elderly patients 4 times more likely to die from treatment complications
5. Using pharmacist-directed service improves quality of care for patients
6. Improving care for bowel cancer patients
7. Early infusion of donor T cells prevents graft versus host disease in blood cancer patients
8. Researchers Craft Blood Vessels for Heart, Kidney Patients
9. Prehabilitation better prepares patients for knee replacement surgery
10. For-Profit Hospices May Prefer Certain Types of Patients: Study
11. Will Loss of Lethal Injection Drug Harm Surgical Patients?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug May Help Patients With Irregular Heartbeat Avoid Stroke
(Date:3/29/2017)... ... March 29, 2017 , ... ... documenting and diagramming network and data center assets and audio-video devices has recently ... request new equipment shapes for free and download shapes and stencils from ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... many scientific laboratories. The assembly protocols involve many repetitive steps and often scientists ... automation, which enables the high-throughput needed, and results in a lower error rate ...
(Date:3/29/2017)... NJ (PRWEB) , ... March 29, 2017 , ... ... School of Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians ... 29 at Intercontinental Time Square, New York. , The program will be ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether Education ... quality, the field must first improve teacher preparation program design. It then asserts ... and that decades of input- and outcome-based research has failed to improve teacher ...
(Date:3/28/2017)... Georgia (PRWEB) , ... March 28, 2017 , ... ... to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, property ... a leader in the real estate valuation industry for more than 40 years. ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017   Royal ... leader in health technology, and PathAI, a company ... collaborating with the aim to develop solutions that ... of cancer and other diseases. The partnership aims ... enabling this form of artificial intelligence to be ...
(Date:3/29/2017)... Stryker announced today that it has been ... partnership with Great Place to Work (GPTW). We ranked ... list highlights the top U.S. companies with 1,000 or ... demonstrating respect, compassion and concern for their employees, their ... the companies on the list, GPTW asked more than ...
(Date:3/29/2017)... SILVER SPRING, Md. , March 29, 2017 On ... Ocrevus (ocrelizumab) to treat adult patients with relapsing forms ... (PPMS). This is the first drug approved by the ... by a health care professional.  "Multiple ... life," said Billy Dunn , M.D., director of ...
Breaking Medicine Technology: